Epigallocatechin gallate (EGCG) for Colon Cancer
This trial is for patients with colon or rectal cancer who haven't received any treatment yet. If they're eligible for surgery, they'll be enrolled and given the chance to either have surgery alone or surgery with a new type of chemotherapy.
- Colon Cancer
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2022 Phase 1 trial • 39 Patients • NCT04177693
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there any other experiments that have been conducted utilizing Epigallocatechin gallate (EGCG)?
"Currently, 3 clinical trials are in-progress that investigate Epigallocatechin gallate (EGCG) with none being at the Phase 3 stage. Despite this, there are a total of 296 research facilities across the world conducting these studies, most notably in Fort Collins, Colorado."
Are there any available opportunities for participants in this experiment?
"Affirmative. As per the information on clinicaltrials.gov, this study is actively seeking participants and was initially listed in January 31st 2017 with its most recent update being December 13th 2021. The sample size consists of 50 patients from a single location."
How many people is this study recruiting?
"Affirmative. The clinical trial registry hosted on clinicaltrials.gov discloses that the study, which was first posted on January 31st 2017, is now actively recruiting 50 participants from 1 different medical site."